-
Je něco špatně v tomto záznamu ?
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study
A. Chiricozzi, SM. Ferrucci, L. Di Nardo, N. Gori, A. Balato, M. Ortoncelli, M. Maurelli, M. Galluzzo, M. Munera Campos, T. Seremet, G. Caldarola, C. De Simone, E. Ippoliti, T. Torres, S. Gkalpakiotis, C. Conrad, JM. Carrascosa, L. Bianchi, G....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu multicentrická studie, časopisecké články
- MeSH
- atopická dermatitida * diagnóza farmakoterapie MeSH
- cíle MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- kohortové studie MeSH
- kvalita života MeSH
- lidé MeSH
- monoklonální protilátky škodlivé účinky MeSH
- retrospektivní studie MeSH
- senioři MeSH
- stupeň závažnosti nemoci MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce. RESEARCH DESIGN AND METHODS: A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts. RESULTS: A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16. CONCLUSIONS: This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.
Department of Dermatology Germans Trias i Pujol University Hospital Badalona Spain
Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan Italy
Department of Systems Medicine University of Rome Tor Vergata Rome Italy
Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
Dermatology Unit Fondazione Policlinico Tor Vergata Rome Italy
Dermatology Unit University of Campania Luigi Vanvitelli Naples Italy
Section of Dermatology and Venereology Department of Medicine University of Verona Verona Italy
Section of Dermatology Department of Medical Sciences University of Turin Turin Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24001288
- 003
- CZ-PrNML
- 005
- 20240213094523.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14712598.2023.2292627 $2 doi
- 035 __
- $a (PubMed)38108300
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Chiricozzi, A $u Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy $u UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy $1 https://orcid.org/0000000267390387
- 245 10
- $a Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study / $c A. Chiricozzi, SM. Ferrucci, L. Di Nardo, N. Gori, A. Balato, M. Ortoncelli, M. Maurelli, M. Galluzzo, M. Munera Campos, T. Seremet, G. Caldarola, C. De Simone, E. Ippoliti, T. Torres, S. Gkalpakiotis, C. Conrad, JM. Carrascosa, L. Bianchi, G. Argenziano, S. Ribero, G. Girolomoni, AV. Marzano, K. Peris, MEDaCoTRA Study Group
- 520 9_
- $a BACKGROUND: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce. RESEARCH DESIGN AND METHODS: A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts. RESULTS: A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16. CONCLUSIONS: This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a atopická dermatitida $x diagnóza $x farmakoterapie $7 D003876
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a cíle $7 D006040
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a kvalita života $7 D011788
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a monoklonální protilátky $x škodlivé účinky $7 D000911
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ferrucci, S M $u Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- 700 1_
- $a Di Nardo, L $u Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy $u UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Gori, N $u Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy $u UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Balato, A $u Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy
- 700 1_
- $a Ortoncelli, M $u Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy
- 700 1_
- $a Maurelli, M $u Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy $1 https://orcid.org/0000000174928010
- 700 1_
- $a Galluzzo, M $u Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy $u Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy $1 https://orcid.org/0000000234245175
- 700 1_
- $a Munera Campos, M $u Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP), Autonomous University of Barcelona (UAB), Badalona, Spain
- 700 1_
- $a Seremet, T $u Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
- 700 1_
- $a Caldarola, G $u Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy $u UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy $1 https://orcid.org/0000000288379232
- 700 1_
- $a De Simone, C $u Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy $u UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Ippoliti, E $u Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy $u UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Torres, T $u Department of Dermatology, Centro Hospitalar Universitário de Santo António, University of Porto, Porto, Portugal $1 https://orcid.org/0000000304040870
- 700 1_
- $a Gkalpakiotis, S $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic
- 700 1_
- $a Conrad, C $u Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
- 700 1_
- $a Carrascosa, J M $u Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP), Autonomous University of Barcelona (UAB), Badalona, Spain
- 700 1_
- $a Bianchi, L $u Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy $u Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy
- 700 1_
- $a Argenziano, G $u Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy
- 700 1_
- $a Ribero, S $u Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy
- 700 1_
- $a Girolomoni, G $u Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
- 700 1_
- $a Marzano, A V $u Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy $u Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
- 700 1_
- $a Peris, K $u Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy $u UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 710 2_
- $a MEDaCoTRA Study Group
- 773 0_
- $w MED00181398 $t Expert opinion on biological therapy $x 1744-7682 $g Roč. 23, č. 12 (2023), s. 1307-1315
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38108300 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213094520 $b ABA008
- 999 __
- $a ok $b bmc $g 2049735 $s 1210982
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 23 $c 12 $d 1307-1315 $e 20231228 $i 1744-7682 $m Expert opinion on biological therapy $n Expert Opin Biol Ther $x MED00181398
- LZP __
- $a Pubmed-20240109
